Zacks Investment Research on MSN6h
AXSM Settles Sunosi Patent Litigation With Hikma Pharmaceuticals
Axsome Therapeutics AXSM announced that it has entered into a settlement agreement with Hikma Pharmaceuticals related to ...
TD Cowen Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)
In a report released today, Joseph Thome from TD Cowen maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report), with a price ...
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Consensus Recommendation of “Buy” from Brokerages
Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report) has earned a consensus rating of “Buy” from the fifteen ratings ...
Axsome Therapeutics, Inc.: Axsome Therapeutics Settles Sunosi (solriamfetol) Patent Litigation with Hikma Pharmaceuticals USA
Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders ...
Axsome Therapeutics settles Sunosi patent litigation with Hikma
Axsome Therapeutics (AXSM) announced that it has entered into a settlement agreement with Hikma Pharmaceuticals (HKMPF), resolving patent ...
Le Lézard1d
PFAS Testing Market worth US$969.5 million by 2030 with 14.5% CAGR | MarketsandMarketstm
The global PFAS Testing Market, valued at US$379.2 million in 2023, is forecasted to grow at a robust CAGR of 14.5%, reaching US$429.2 million in 2024 and an impressive US$969.5 million by 2030. The ...
Axsome resolves patent dispute with Hikma
Axsome Therapeutics (AXSM) stock gains as company settles patent dispute with Hikma (HKMPF) over sleep therapy Sunosi. Read ...
Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Hikma Pharmaceuticals USA
Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central ...
Axsome Therapeutics (NASDAQ:AXSM) Stock Price Expected to Rise, Robert W. Baird Analyst Says
Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its price objective hoisted by stock analysts at Robert W. Baird from ...
Zacks Investment Research on MSN2d
AXSM Gets Positive FDA Feedback for Alzheimer's Agitation Drug Filing
Axsome Therapeutics AXSM announced that it has received formal feedback from the FDA on its plans to seek approval for AXS-05 ...
Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer’s Disease Agitation Supporting NDA Submission
Supplemental New Drug Application (sNDA) submission anticipated in 3Q 2025NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Axsome ...
Why Axsome Therapeutics, Inc. (AXSM) is Skyrocketing So Far in 2025
We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where Axsome Therapeutics, Inc.